Status: Recruiting
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics, anti-drug antibodies, and neutralizing activity of MDX2301 administered by intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes in healthy adults and adults at higher risk for severe COVID-19. Participants will receive single IV, IM, and SC doses of MDX2301 or placebo and a repeat IM or SC dose approximately 3 months apart of MDX2301 or placebo.
Participants needed: 80
Trial details
Phase: Phase 1Age: 18-64Biological sex: AllType: InterventionalSponsor: ModeX Therapeutics, An OPKO Health CompanyUpdated: May 18, 2026Locations: 2
Eligibility criteria
Participant is a healthy male or female, 18 to 64 years of age. [+18]
Participant has any chronic or significant medical condition that, in the opinio... [+22]